Patent
Water soluble furoxan derivatives having antitumor activity
| العنوان: | Water soluble furoxan derivatives having antitumor activity |
|---|---|
| Patent Number: | 8,946,271 |
| تاريخ النشر: | February 03, 2015 |
| Appl. No: | 13/522026 |
| Application Filed: | February 23, 2011 |
| مستخلص: | Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described. |
| Inventors: | Viola, Antonella (Milan, IT); Bronte, Enzo (Padua, IT); Crosetti, Marco (Milan, IT); Lazzarato, Loretta (Milan, IT); Fruttero, Roberta (Milan, IT); Gasco, Alberto (Milan, IT) |
| Assignees: | Humanitas Mirasole S.p.A. (Rozzano (MI), IT), Istituto Oncologico Veneto IRCCS (Padua, IT) |
| Claim: | 1. A compound having a formula selected from the group consisting of: [chemical expression included] and pharmaceutically acceptable salts thereof. |
| Claim: | 2. A method for the treatment of a pathology characterised by the generation of reactive nitrogen species, comprising the step of administering to a patient in need thereof of a pharmacologically effective amount of the compound of claim 1 . |
| Claim: | 3. The method of claim 2 , wherein said pathology is selected from the group consisting of neoplasia, inflammatory disease and chronic infection. |
| Claim: | 4. The method of claim 3 , wherein said pathology is prostate cancer. |
| Claim: | 5. A method for stimulating the immune response against neoplastic cells comprising administering to a subject in need thereof a pharmacologically effective amount of the compound of claim 1 . |
| Claim: | 6. The method of claim 5 , wherein the neoplastic cells are associated with prostate cancer. |
| Claim: | 7. A pharmaceutical composition comprising the compound of claim 1 . |
| Claim: | 8. The pharmaceutical composition of claim 7 comprising pharmaceutically acceptable excipients and additives selected from the group consisting of: diluents, solvents, bulking agents, rheological modifiers, stabilisers, pH stabilisers, bonding agents, buffers, disaggregating agents, preservatives, elasticizing agents, emulsifiers, chelating agents, lubricating agents, edulcorants, sweetening agents, colouring agents and flavouring agents, alone or in any combination thereof. |
| Current U.S. Class: | 514/364 |
| Patent References Cited: | 2008/0293781 November 2008 Gasco et al. 2010081488 July 2010 |
| Other References: | Turnbull et al. British Journal of Pharmacology 2006, 148, 517-526. cited by examiner Clara Cena, Marco L.Lolli, Loretta Lazzarato, Elena Guaita, Giuseppina Morini, Gabriella Coruzzi, Stuart P. McElroy, Ian L. Megson, Roberta Fruttero and Alberto Gasco, Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New No-Donor Esters of Aspirin, Journal of Medicinal Chemistry, 2003, pp. 747-754, vol. 46, No. 5, American Chemical Society, Washington, DOI: 1021/JM020969T. cited by applicant Claudio Medana, Antonella Di Stilo, Sonja Visentin, Roberta Fruttero, Alberto Gasco, Dario Ghigo and Amalia Bosia, No Donor and Biological Properties of Different Benzofuroxans, Pharmaceutical Research, Kluwer Academic Publishers, Jun. 1, 1999, pp. 956-960, vol. 16, No. 6, Plenum Publishing Corporation, New York, DOI: 10.1023/A: 1018974409622. cited by applicant Database Beilstein (online), Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; 1931, Frejka et al.: XP002600024, Database accession No. 3178253. cited by applicant |
| Assistant Examiner: | Coughlin, Matthew |
| Primary Examiner: | Kosack, Joseph |
| Attorney, Agent or Firm: | Alderson Jr., Robert E. |
| رقم الانضمام: | edspgr.08946271 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |